Understanding Your Laboratory Test: A Patient's Guide to What It Is, Why It Is Done, and What the Results Mean
This test measures the level of a specific fatty acid metabolite in amniotic fluid to help detect metabolic disorders in the unborn baby.
{"Measures C16:1-OH acylcarnitine levels in amniotic fluid","Helps screen for fatty acid oxidation disorders before birth","Used when there's a family history of metabolic diseases","Abnormal results may indicate genetic metabolic conditions","Results guide doctors in planning appropriate care"}
Key facts at a glance
- LOINC
- 50120-5
- Short code
- 3OH-Palmitoleylcarn Amn-sCnc
- Synonyms
- 3OH-Palmitoleylcarn Amn-sCnc
- Category
- chemistry
- Sample
- fluid
- Container
- Sterile tube
- Units
- N/A
- Fasting
- false
- Population
- adult
- Sex
- all
- Age range
- 18–65 years
- Specimen volume
- 2-5 mL
- Stability
- Room temperature: 2h, Refrigerated: 24h
- Hemolysis max
- 300
- TAT
- 4–24 hours
- Order
- routine
This test is a medical laboratory procedure in which a sample, such as blood, urine, or another body specimen, is collected and analyzed to help your healthcare provider evaluate how your body is functioning and check for signs of disease or other health concerns.
The 3-Hydroxypalmitoleylcarnitine (C16:1-OH) test measures the amount of a specific type of acylcarnitine in the amniotic fluid that surrounds your baby during pregnancy. Acylcarnitines are substances produced when the body breaks down fatty acids for energy. This particular acylcarnitine (C16:1-OH) is normally present in very small amounts, but elevated levels can indicate that your baby may have a problem with how their body processes certain fats for energy.
This test is performed to help diagnose a medical condition, monitor an illness you already have, or screen for health problems before symptoms appear, giving your provider important information to guide treatment decisions and follow-up care.
This test is primarily performed during pregnancy when there is a family history of metabolic disorders, particularly fatty acid oxidation disorders or organic acidemias. These are genetic conditions where the body cannot properly break down certain fats or proteins for energy. Early detection through amniotic fluid testing allows healthcare providers to prepare for special care needs your baby may need immediately after birth.
The test is done by a trained healthcare professional who collects the required sample in a clinic, hospital, or laboratory setting; the specimen is then sent for analysis, and your results are typically returned to your provider within a few days.
The test requires a sample of amniotic fluid, which is collected during a procedure called amniocentesis. During amniocentesis, a thin needle is used to withdraw a small amount of amniotic fluid from the uterus under ultrasound guidance. The fluid is then sent to a laboratory where specialists measure the levels of C16:1-OH and other acylcarnitines.
Your results are compared with standard reference ranges, and values that fall higher or lower than normal may suggest infection, inflammation, organ dysfunction, or another condition, but only your healthcare provider can interpret them correctly based on your symptoms, history, and overall health.
Normal levels of C16:1-OH in amniotic fluid indicate that your baby likely does not have the specific metabolic disorders this test screens for. Elevated levels may suggest that your baby has a fatty acid oxidation disorder or another metabolic condition. However, abnormal results require further testing and consultation with a metabolic specialist to confirm a diagnosis.
Clinical interpretation
How abnormal results are interpreted and what conditions they suggest.
The C16:1-OH test in amniotic fluid is primarily used for prenatal screening of fatty acid oxidation disorders. These inherited conditions can cause serious health problems, including low blood sugar, muscle weakness, and energy crises, especially during periods of fasting or illness. Early detection allows for immediate intervention after birth, including special diets and avoidance of fasting, which can prevent life-threatening complications.
Elevated C16:1-OH levels in amniotic fluid may indicate conditions such as medium-chain acyl-CoA dehydrogenase deficiency (MCAD), multiple acyl-CoA dehydrogenase deficiency (MADD), or other fatty acid oxidation disorders. These conditions are caused by genetic mutations that affect enzymes needed to break down fatty acids. Knowing the diagnosis before birth enables the healthcare team to plan for specialized newborn care, including prompt testing and treatment.
This test is often part of a broader metabolic screening panel that measures multiple acylcarnitines in amniotic fluid. The pattern of different acylcarnitine elevations helps doctors determine the specific type of metabolic disorder. Results are interpreted in the context of family history, gestational age, and other clinical findings. Genetic counseling is typically recommended when abnormal results are found.
Frequently asked questions
Is amniocentesis safe?
What happens if the results are abnormal?
Can this test tell me exactly what condition my baby has?
Will my baby need special care after birth?
Is this test mandatory?
Sources
- 1
- 2
- 3
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy